A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges

J Natl Cancer Inst. 1999 Jan 20;91(2):102-3. doi: 10.1093/jnci/91.2.102.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Benzamides
  • Enzyme Inhibitors / pharmacology*
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate
  • Leukemia, Experimental / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Piperazines / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / pharmacology*
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl